Gene therapy for ocular angiogenesis.
Ocular neovascularization is a central feature of diabetic retinopathy and age-related macular degeneration. These conditions are the major causes of blindness in the developed world. Current treatments are of limited efficacy and associated with significant adverse effects. Characterization of the molecular and cellular events involved in angiogenesis has led to the identification of a number of angiostatic molecules with potential therapeutic value. The systemic administration of small molecule angiostatic proteins risks significant systemic adverse effects and the effect of their intraocular injection is short-lived. Local gene transfer, however, offers the possibility of targeted, sustained and regulatable delivery of angiostatic proteins to the retina after a single procedure to introduce a vector to an intraocular site. The effect of intra-ocular delivery of recombinant viruses carrying genes encoding angiostatic proteins has been demonstrated in rodent models of ocular neovascularization. Recombinant adeno-associated virus-mediated local gene transfer of a vascular endothelial growth factor inhibitor controls both retinal and choroidal neovascularization. The clinical application of this approach may require the means to regulate gene expression in order to minimize the potential for adverse effects. Regulation of transgene expression by means of a hypoxia-responsive promoter offers an attractive strategy for the targeted and regulated delivery of angiostatic proteins to the retina in the management of ischaemia-induced ocular neovascularization. Preclinical studies of gene transfer in a large animal model following subretinal delivery of a recombinant adeno-associated virus vector have demonstrated efficient sustained reporter gene expression in cells of the outer retina. Recent progress has enabled the planning of clinical trials of gene therapy for ocular neovascular disorders.
Bainbridge
James W B
JW
Department of Molecular Genetics, Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, U.K. j.bainbridge@ucl.ac.uk
Mistry
Ajay R
AR
Thrasher
Adrian J
AJ
Ali
Robin R
RR
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000235:genetics* / Q000627:therapeutic use; D000818:Animals; D020256:Choroidal Neovascularization / Q000628:therapy; D000229:Dependovirus / Q000235:genetics; D003930:Diabetic Retinopathy / Q000628:therapy*; D016326:Extracellular Matrix Proteins / Q000235:genetics; D018014:Gene Transfer Techniques; D005818:Genetic Engineering / Q000009:adverse effects; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D008268:Macular Degeneration / Q000628:therapy*; D051379:Mice; D018995:Myosin Heavy Chains; D024501:Nonmuscle Myosin Type IIB; D012107:Research Design; D012160:Retina / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D016326:Extracellular Matrix Proteins; D024501:Nonmuscle Myosin Type IIB; C103815:nonmuscle myosin type IIB heavy chain; D018995:Myosin Heavy Chains